Skip to main content

MoneyWorks4Me

Biocon informs about press release

16 Nov 2026 Evaluate
Biocon has informed that it enclosed the press release titled ‘Biocon Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection, a Biosimilar to Perjeta®, Expanding Its Oncology Portfolio”. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1870.30
Dr. Reddys Labs. 1383.30
Cipla 1389.95
Lupin 1951.80
Zydus Lifesciences 1202.70
View more..